Da steht eine Neubewertung an: Genesis Technology - 500 Beiträge pro Seite
eröffnet am 14.07.07 20:23:07 von
neuester Beitrag 15.07.07 19:09:14 von
neuester Beitrag 15.07.07 19:09:14 von
Beiträge: 2
ID: 1.130.348
ID: 1.130.348
Aufrufe heute: 0
Gesamt: 2.987
Gesamt: 2.987
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 43 Minuten | 3622 | |
vor 46 Minuten | 3059 | |
vor 1 Stunde | 1736 | |
gestern 21:04 | 1137 | |
vor 57 Minuten | 1102 | |
heute 10:21 | 1072 | |
heute 06:53 | 862 | |
vor 1 Stunde | 773 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.309,77 | +0,51 | 283 | |||
2. | 3. | 171,64 | +0,02 | 77 | |||
3. | 4. | 1,1200 | -12,50 | 75 | |||
4. | 2. | 10,320 | -2,46 | 72 | |||
5. | 13. | 0,1995 | +3,64 | 38 | |||
6. | 8. | 6,8220 | +0,12 | 38 | |||
7. | 6. | 7,0280 | +1,56 | 37 | |||
8. | 18. | 10,100 | -7,00 | 36 |
Genesis vor einem Ausbruch!
Die Beteilung Lotus ist am Freitag um mehr als 50 % gestiegen.
Hohe Umsätze und deutlich Anstieg in den letzten Tagen bei Genesis.
Wie sieht Ihr die Bewertung und das kurzfristige Potential?
Die Beteilung Lotus ist am Freitag um mehr als 50 % gestiegen.
Hohe Umsätze und deutlich Anstieg in den letzten Tagen bei Genesis.
Wie sieht Ihr die Bewertung und das kurzfristige Potential?
kurzfristig Verdopplungsgefahr
PS: Mcal deutlich unter NAV und KGV von < 4
Genesis Partner, Lotus Pharmaceuticals, Announces Development of Hepatitis B Drug and Retail Outlet Expansion
Genesis Technology Group, Inc. (OTCBB: GTEC)
BOCA RATON, Fla., July 13, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) announced that its Beijing pharmaceutical partner, Lotus Pharmaceuticals, Inc., has advanced in the development of a treatment for Hepatitis B and also increased its number of local outlets to 15 retail stores.
Lotus (OTC BB:LTUS.OB - News) was recently joined by Gold Horse International, Inc. (OTC BB:SPEH.OB - News) as graduates from the Genesis capital growth partnering program. Genesis maintains a significant equity position in each company, and provides management and marketing guidance on a continual basis. Four other Chinese companies, at various stages of the program, are under contract.
Dr. Liu Zhongyi, Lotus CEO and founder, announced: ``In April 2007, our Company invested about $750,000 to develop injectable Ganbifu, which is primarily used for the treatment of chronic viral type B Hepatitis or HBV.
``This medication is very effective in treating HBV. We are now starting the required animal experimentation. It is expected to reach the market in 2009, and its annual sales revenues are forecast up to $20 million annually, with profits approaching $6 million.''
Lotus also announced that it has established five new local retail drug stores. The Company estimates that annual sales revenues, from these outlets, should be as much as $2 million, with net profits forecast up to $500,000. This will bring the total number Lotus retail drug stores to 15 in Greater Beijing.
Dr. Liu added: ``Starting this month, Lotus will spend about $100,000 each month in the nationally-distributed Health Daily to build the company's image and extensively advertise our products. Lotus is committed to expanding its market share in an effort to become a national brand.''
About Genesis Technology Group, Inc.
PS: Mcal deutlich unter NAV und KGV von < 4
Genesis Partner, Lotus Pharmaceuticals, Announces Development of Hepatitis B Drug and Retail Outlet Expansion
Genesis Technology Group, Inc. (OTCBB: GTEC)
BOCA RATON, Fla., July 13, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) announced that its Beijing pharmaceutical partner, Lotus Pharmaceuticals, Inc., has advanced in the development of a treatment for Hepatitis B and also increased its number of local outlets to 15 retail stores.
Lotus (OTC BB:LTUS.OB - News) was recently joined by Gold Horse International, Inc. (OTC BB:SPEH.OB - News) as graduates from the Genesis capital growth partnering program. Genesis maintains a significant equity position in each company, and provides management and marketing guidance on a continual basis. Four other Chinese companies, at various stages of the program, are under contract.
Dr. Liu Zhongyi, Lotus CEO and founder, announced: ``In April 2007, our Company invested about $750,000 to develop injectable Ganbifu, which is primarily used for the treatment of chronic viral type B Hepatitis or HBV.
``This medication is very effective in treating HBV. We are now starting the required animal experimentation. It is expected to reach the market in 2009, and its annual sales revenues are forecast up to $20 million annually, with profits approaching $6 million.''
Lotus also announced that it has established five new local retail drug stores. The Company estimates that annual sales revenues, from these outlets, should be as much as $2 million, with net profits forecast up to $500,000. This will bring the total number Lotus retail drug stores to 15 in Greater Beijing.
Dr. Liu added: ``Starting this month, Lotus will spend about $100,000 each month in the nationally-distributed Health Daily to build the company's image and extensively advertise our products. Lotus is committed to expanding its market share in an effort to become a national brand.''
About Genesis Technology Group, Inc.
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
283 | ||
77 | ||
75 | ||
72 | ||
38 | ||
38 | ||
37 | ||
36 | ||
33 | ||
33 |
Wertpapier | Beiträge | |
---|---|---|
31 | ||
30 | ||
27 | ||
27 | ||
25 | ||
22 | ||
21 | ||
19 | ||
19 | ||
19 |